Scinai Raises $4M in Private Placement and Warrant Inducement

Updates

1. Oct 16, 10:05 AM ET · SEC 6-K — Scinai closed the $4.0M financing: 2,458,334 ADSs plus Series A-1 warrants for 3,687,501 ADSs, and induced exercise of 879,194 existing warrants at $1.20 per ADS.

   • Financing Proceeds — Aggregate gross proceeds from the private placement and warrant inducement transaction were approximately $4.0 million, before deducting placement agent fees and expenses.
   • Private Placement — The private placement consisted of 2,458,334 ADSs (or pre-funded warrants in lieu thereof), each ADS representing 40,000 ordinary shares.
   • Series A-1 Warrants — Series A-1 Warrants to purchase up to 3,687,501 ADSs were issued together with the private placement ADSs.
   • Existing Warrant Exercise — Existing Warrants to purchase up to 879,194 ADSs were exercised at a reduced exercise price of $1.20 per ADS.
   • New Warrants — Additional Series A-1 Warrants (the "New Warrants") to purchase up to 1,318,791 ADSs were issued.
   • Placement Agent — A.G.P./Alliance Global Partners acted as the sole placement agent for the transactions.
   • Registration and Exemption
     • The Company agreed to file a registration statement with the SEC to register for resale the ADSs issued in the private placement, the ADSs issuable upon exercise of the pre-funded warrants and New Warrants, and the underlying ordinary shares.
     • Company agreed to file a registration statement with the SEC to register for resale the private placement ADSs, ADSs issuable upon exercise of pre-funded warrants and New Warrants, and underlying ordinary shares.
     • Company agreed to file a registration statement with the SEC to register for resale the private placement ADSs, ADSs issuable upon exercise of pre-funded warrants and New Warrants, and underlying ordinary shares.
     • The offer and sale of the securities in the private placement and the New Warrants was made in reliance on an exemption from registration under Section 4(a)(2) of the Securities Act and Regulation D promulgated thereunder.
     • Offer and sale of securities in the private placement and the New Warrants made in reliance on exemption under Section 4(a)(2) of the Securities Act and Regulation D promulgated thereunder.
     • The ADSs issued upon exercise of the Existing Warrants have been registered for resale pursuant to the Company's effective registration statement on Form F-3 (File No. 333-295698).
     • ADSs issued upon exercise of the Existing Warrants registered for resale pursuant to the Company's effective registration statement on Form F-3 (File No. 333-295698).
   • Use of Proceeds — Net proceeds, together with existing cash resources, are intended to advance current customer programs, pursue additional CDMO contracts and continue selective investment in its immunotherapy pipeline.
   • Closing Date — The closing was announced on October 16, 2026.
   All 27 details

   • Aggregate gross proceeds from the private placement and warrant inducement transaction were approximately $4.0 million, before deducting placement agent fees and expenses.
   • Each ADS represents 40,000 ordinary shares.
   • Existing Warrants to purchase up to 879,194 ADSs were exercised at a reduced exercise price of $1.20 per ADS.
   • Additional Series A-1 Warrants to purchase up to 1,318,791 ADSs (the "New Warrants") were issued.
   • A.G.P./Alliance Global Partners acted as the sole placement agent for the transactions.
   • The Company agreed to file a registration statement with the SEC to register for resale the ADSs issued in the private placement, the ADSs issuable upon exercise of the pre-funded warrants and New Warrants, and the underlying ordinary shares.
   • The offer and sale of the securities in the private placement and the New Warrants was made in reliance on an exemption from registration under Section 4(a)(2) of the Securities Act and Regulation D promulgated thereunder.
   • The ADSs issued upon exercise of the Existing Warrants have been registered for resale pursuant to the Company's effective registration statement on Form F-3 (File No. 333-295698).
   • Private placement of 2,458,334 ADSs (or pre-funded warrants in lieu thereof), each ADS representing 40,000 ordinary shares.
   • Series A-1 Warrants to purchase up to 3,687,501 ADSs issued together with the private placement ADSs.
   • Existing Warrants to purchase up to 879,194 ADSs exercised at a reduced exercise price of $1.20 per ADS.
   • Additional Series A-1 Warrants (the "New Warrants") to purchase up to 1,318,791 ADSs issued.
   • Aggregate gross proceeds from the private placement and warrant inducement transaction approximately $4.0 million, before deducting placement agent fees and expenses.
   • A.G.P./Alliance Global Partners acted as the sole placement agent for the transactions.
   • Company agreed to file a registration statement with the SEC to register for resale the private placement ADSs, ADSs issuable upon exercise of pre-funded warrants and New Warrants, and underlying ordinary shares.
   • Offer and sale of securities in the private placement and the New Warrants made in reliance on exemption under Section 4(a)(2) of the Securities Act and Regulation D promulgated thereunder.
   • ADSs issued upon exercise of the Existing Warrants registered for resale pursuant to the Company's effective registration statement on Form F-3 (File No. 333-295698).
   • Net proceeds, together with existing cash resources, intended to advance current customer programs, pursue additional CDMO contracts and continue selective investment in its immunotherapy pipeline.
   • Closing announced October 16, 2026.
   • Private placement of 2,458,334 ADSs, each ADS representing 40,000 ordinary shares.
   • Series A-1 Warrants to purchase up to 3,687,501 ADSs issued with the private placement.
   • Existing Warrants for 879,194 ADSs exercised at a reduced exercise price of $1.20 per ADS.
   • Additional Series A-1 Warrants to purchase up to 1,318,791 ADSs (the New Warrants) issued.
   • Aggregate gross proceeds approximately $4.0 million, before deducting placement agent fees and expenses.
   • A.G.P./Alliance Global Partners acted as sole placement agent.
   • Company agreed to file a registration statement with the SEC to register for resale the private placement ADSs, ADSs issuable upon exercise of pre-funded warrants and New Warrants, and underlying ordinary shares.
   • Net proceeds, with existing cash resources, intended to advance current customer programs, pursue additional CDMO contracts and continue selective investment in its immunotherapy pipeline.